Febuxostat-d9
Febuxostat-d9 Basic information
- Product Name:
- Febuxostat-d9
- Synonyms:
-
- Febuxostat-d9
- 2-(3-Cyano-4-isobutyloxyphenyl-d9)-4-Methyl-5-thiazolecarboxylic Acid
- 2-[3-Cyano-4-(2-Methylpropoxy-d9)phenyl]-4-Methyl-5-thiazolecarboxylic Acid
- TEI 6720-d9
- TMX 67-d9
- [2H9]-Febuxostat
- Febuxostat-d9 (2-methylpropoxy-d9)
- Febuxostat D9Q: What is Febuxostat D9 Q: What is the CAS Number of Febuxostat D9 Q: What is the storage condition of Febuxostat D9 Q: What are the applications of Febuxostat D9
- CAS:
- 1246819-50-0
- MF:
- C16H16N2O3S
- MW:
- 316.37484
- Product Categories:
-
- Inhibitors
- Intermediates & Fine Chemicals
- Heterocycles
- Isotope Labelled Compounds
- Pharmaceuticals
- Mol File:
- 1246819-50-0.mol
Febuxostat-d9 Chemical Properties
- Melting point:
- >201°C (dec.)
- storage temp.
- Refrigerator
- solubility
- Chloroform (Slightly), Methanol (Slightly)
- form
- Solid
- color
- White to Off-White
Febuxostat-d9 Usage And Synthesis
Description
Febuxostat-d9 is intended for use as an internal standard for the quantification of febuxostat by GC- or LC-MS. Febuxostat is an antihyperuricemic nonpurine inhibitor of both the oxidized and reduced forms of xanthine oxidase. It inhibits bovine milk xanthine oxidase as well as mouse and rat liver xanthine oxidase/xanthine dehydrogenase (IC50s = 1.4, 1.8, and 2.2 nM, respectively). It is 10-30 times more potent than the hypoxanthine analog allopurinol (; Kis = 0.7 nM and 0.7 μM, respectively). Febuxostat decreases the serum level of urate in a potassium oxonate rat model of hyperuricemia (ED50 = 1.5 mg/kg). It reduces hepatic macrovesicular steatosis in mice fed a high-fat diet containing trans fatty acids when administered at a dose of 1 mg/kg per day. Febuxostat (0.75 mg/kg) also increases CNS expression of glutamate oxaloacetate transaminase 2 (GOT2) and improves neurological symptoms in a mouse model of secondary progressive experimental autoimmune encephalomyelitis (EAE). Formulations containing febuxostat have been used in the treatment of symptomatic hyperuricemia in patients with gout.
Uses
Febuxostat-d9 is a Labeled compound, intended for use as an internal standard for the quantification of Febuxostat by GC- or LC-mass spectrometry.
Uses
Labelled Febuxostat (F229000). Xanthine oxidase/xanthine dehydrogenase inhibitor. Used for treatment of hyperuricemia and chronic gout.
Febuxostat-d9Supplier
- Tel
- 010-82848833 400-666-7788
- jkinfo@jkchemical.com
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 0755-0755-66853366 13670046396
- sales@chem-strong.com
- Tel
- 0575-18780151478 18582380095
- sales@artisbio.com
- Tel
- 021-65675885 18964387627
- info@efebio.com
Febuxostat-d9(1246819-50-0)Related Product Information
- Febuxostat
- 2-HYDROXY-THIOBENZAMIDE
- 2-[3-Carboxy-4-(2-Methylpropoxy)phenyl]-4-Methyl-5-thiazolecarboxylic Acid
- 2-[3-(AMinocarbonyl)-4-(2-Methylpropoxy)phenyl]-4-Methyl-5-thiazolecarboxylic Acid
- Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate
- Febuxostat impurity 37
- FeBuxostat Impurity 33
- 3-Cyano-4-isobutoxybenzoic acid
- ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methyl thiazole-5-carboxylate
- ETHYL 2-(3-FORMYL-4-ISOBUTOXYPHENYL)-4-METHYLTHIAZOLE-5-CARBOXYLATE
- 4-ISOBUTOXY-BENZALDEHYDE
- 2-(3-cyano-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid
- Febuxostat Impurity 6
- 3-Cyano-4-(2-methylpropoxy)benzenecarbothioamide
- isopropyl 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate
- Febuxostat Impurity 8
- Febuxostat Impurity 14
- Febuxostat Bromo Impurity